Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Clinical Trial of RVU120 in Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia With or Without NPM1 Mutation (RIVER-52)

NCT06268574 is registered in ClinicalTrials.gov with Ryvu Therapeutics SA as lead sponsor.

NCT NCT06268574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06268574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Clinical Trial of RVU120 in Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia With or Without NPM1 Mutation (RIVER-52)
Lead sponsor
Ryvu Therapeutics SA
Phase
Phase 2
Overall status
Terminated
Start date
January 23, 2024
Completion date
September 5, 2025
Enrollment
62 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), high-risk myelodysplastic syndrome